A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/22 (2006.01) A61K 9/52 (2006.01) A61K 47/00 (2006.01) A61P 1/04 (2006.01)
Patent
CA 2434542
The present invention is directed to a multiparticulate, modified release solid dispersion formulation, comprising a drug substance having a pH- dependent solubility, said drug substance being a compound of the formula I, or a pharmaceutically acceptable salt thereof; a hydrophobic matrix former which is a water-insoluble, non-swelling amphiphilic lipid; and a hydrophilic matrix former which is a meltable, water-soluble excipient; wherein the weight ratio hydrophobic matrix former/hydrophilic matrix former is >=1; and the particle size is less than 300 ~m. Also a unit dosage of the same, as well as a process for the preparation thereof and the use of the formulation and unit dosage is claimed.
L'invention concerne une préparation multiparticulaire de dispersion solide à libération modifiée comprenant une substance médicamenteuse dont la solubilité dépend du pH, cette substance étant un composé de formule I ou un sel acceptable sur le plan pharmaceutique de celui-ci; un agent hydrophobe de formation de matrice qui est un lipide insoluble dans l'eau, non gonflant et amphiphile; et un agent hydrophile de formation de matrice qui est un excipient fusible hydrosoluble; le rapport pondéral entre l'agent hydrophobe de formation de matrice et l'agent hydrophile de formation de matrice étant >=1; et la granulométrie étant inférieure à environ 300 µm. L'invention concerne également un dosage unitaire de celle-ci et un procédé de préparation et d'utilisation associé, ainsi qu'un dosage unitaire.
Astrazeneca Ab
Fetherstonhaugh & Co.
LandOfFree
Novel modified release formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel modified release formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel modified release formulation will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1734229